# Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

> **NCT01465243** · PHASE4 · COMPLETED · sponsor: **Betta Pharmaceuticals Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Icotinib

## Key facts

- **NCT ID:** NCT01465243
- **Lead sponsor:** Betta Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-10
- **Final completion:** 2014-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01465243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01465243, "Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01465243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*